Effects of human ANF-(99–126) on sympathetic nerve function, hemodynamic parameters and plasma cGMP levels in anesthetized, ganglion-blocked dogs

Bergey, James L.; Much, David R.; Kratunis, V J; Asaad, Magdi M.

doi:10.1016/0014-2999(89)90694-8

Cited by 13 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ANP is produced primarily in the cardiac atria in response to atrial stretch. It produces a direct depressant action on sympathetic nerve function that is associated with a reduction in both cardiac output and arterial blood pressure in dogs (Bergey et al 1989) and heart failure patients (Abramson et al 1999;Kasama et al 2004). ANP does not appear to alter the heart rate response to peripheral vagal stimulation in vitro or release of acetylcholine in vitro (Hiwatari et al 1986).…”

Section: Natriuretic Peptides-particulate Guanylyl Cyclase-cgmp Signamentioning

confidence: 99%

See 1 more Smart Citation

Cyclic nucleotide regulation of cardiac sympatho‐vagal responsiveness

Paterson

2016

The Journal of Physiology

View full text Add to dashboard Cite

Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are now recognized as important intracellular signalling molecules that modulate cardiac sympatho‐vagal balance in the progression of heart disease. Recent studies have identified that a significant component of autonomic dysfunction associated with several cardiovascular pathologies resides at the end organ, and is coupled to impairment of cyclic nucleotide targeted pathways linked to abnormal intracellular calcium handling and cardiac neurotransmission. Emerging evidence also suggests that cyclic nucleotide coupled phosphodiesterases (PDEs) play a key role limiting the hydrolysis of cAMP and cGMP in disease, and as a consequence this influences the action of the nucleotide on its downstream biological target. In this review, we illustrate the action of nitric oxide–CAPON signalling and brain natriuretic peptide on cGMP and cAMP regulation of cardiac sympatho‐vagal transmission in hypertension and ischaemic heart disease. Moreover, we address how PDE2A is now emerging as a major target that affects the efficacy of soluble/particulate guanylate cyclase coupling to cGMP in cardiac dysautonomia.

show abstract

Section: Natriuretic Peptides-particulate Guanylyl Cyclase-cgmp Signamentioning

confidence: 99%

“…It produces a direct depressant action on sympathetic nerve function that is associated with a reduction in both cardiac output and arterial blood pressure in dogs (Bergey et al . ) and heart failure patients (Abramson et al . ; Kasama et al .…”

Section: Introductionmentioning

confidence: 99%

Cyclic nucleotide regulation of cardiac sympatho‐vagal responsiveness

Paterson

2016

The Journal of Physiology

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated a direct sympathoinhibitory effect of ANP in vitro as well as in vivo (Drewett et al, 1988;Zukowska-Grojec et al, 1986;Debinski et al, 1987b;Bergey et al, 1989;Floras, 1990). Therefore, in addition to a direct parasympathomimetic effect, we may speculate that ANP enhanced cholinergic outflow through sympathetic inhibition and induced a small bronchoconstriction that is reduced by atropine.…”

Section: Discussionmentioning

confidence: 75%

Muscarinic effect of atrial natriuretic peptide on rabbit airways

Robichaud

Saunier

Michoud

et al. 1993

British J Pharmacology

View full text Add to dashboard Cite

1 The aim of the present work was to investigate under which circumstances atrial natriuretic peptide (ANP) modulates airway resistance. 2 Of the six groups of rabbits (n = 5) studied, three received an infusion of ANP (80 ng min' kg-' i.v.) for a period of 100 min, while the other three were infused with the vehicle. Before receiving the infusion of ANP or the vehicle, the animals were pretreated with atropine (0.5 mg kg-' i.v.), propranolol (2 mg kg-' i.v.) or not pretreated. After 75 min of infusion of ANP, bronchoconstriction was induced by inhalation of histamine. Respiratory resistance (Rrs) was measured before and 3, 5, 10, 15 and 20 min post-histamine challenge. 3 Following 75 min of ANP infusion, plasma ANP concentration increased from 153 ± 52 (mean ± s.e.mean) to 1441 ± 203 pg ml' (P <0.05) without affecting baseline Rrs. Control Rrs values (12.5-20.4 cmH2OP's) were significantly increased following the inhalation of histamine (P<0.001). By themselves, atropine, propranolol or ANP did not modify the histamine-induced increase in Rrs. However, when the animals were pretreated with atropine, ANP infusion significantly reduced the increase in Rrs induced by histamine (30 ± 2 vs 51 ± 6 cmH2O 1' S; P <0.05). 4 These data suggest that ANP has an indirect modulating effect on the airway smooth muscle and will decrease Rrs when muscarinic receptors are blocked.

show abstract

“…In this regard, observations of ANP staining in nerve fibres that are close to sympathetic nerve fibres are of interest (Hansson and Forsgren, 1993). Furthermore, ANP has been reported to have a direct presynaptic depressive effect on sympathetic neurotransmission (Bergey et al, 1989;Kuchel et al, 1987) and to attenuate the release of norepinephrine (Nakamura and Inagami, 1986). It has also been shown that ANP augments cardiac parasympathetic effects (Ackermann et al, 1988;Atchison and Ackermann, 1990).…”

Section: Atrial Natriuretic Peptide Andmentioning

confidence: 93%

Natriuretic peptides in relation to the cardiac innervation and conduction system

Hansson

2002

Microscopy Res & Technique

View full text Add to dashboard Cite

During the past two decades, the heart has been known to undergo endocrine action, harbouring peptides with hormonal activities. These, termed "atrial natriuretic peptide (ANP)," "brain natriuretic peptide (BNP)," and "C-type natriuretic peptide (CNP)," are polypeptides mainly produced in the cardiac myocardium, where they are released into the circulation, producing profound hypotensive effects due to their diuretic, natriuretic, and vascular dilatory properties. It is, furthermore, well established that cardiac disorders such as congestive heart failure and different forms of cardiomyopathy are combined with increased expression of ANP and BNP, leading to elevated levels of these peptides in the plasma. Besides the occurrence of natriuretic peptides (NPs) in the ordinary myocardium, the presence of ANP in the cardiac conduction system has been described. There is also evidence of ANP gene expression in nervous tissue such as the nodose ganglion and the superior cervical ganglion of the rat, ganglia known to be involved in the neuronal regulation of the heart. Furthermore, in the mammalian heart, ANP appears to affect the cardiac autonomic nervous system by sympathoinhibitory and vagoexcitatory actions. This article provides an overview of the relationship between the cardiac conduction system, the cardiac innervation and NPs in the mammalian heart and provides data for the concept that ANP is also involved in neuronal cardiac regulation.

show abstract

Effects of human ANF-(99–126) on sympathetic nerve function, hemodynamic parameters and plasma cGMP levels in anesthetized, ganglion-blocked dogs

Cited by 13 publications

References 17 publications

Cyclic nucleotide regulation of cardiac sympatho‐vagal responsiveness

Cyclic nucleotide regulation of cardiac sympatho‐vagal responsiveness

Muscarinic effect of atrial natriuretic peptide on rabbit airways

Natriuretic peptides in relation to the cardiac innervation and conduction system

Contact Info

Product

Resources

About